- Kezar Life Sciences Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 12, 2023
- Kezar Life Sciences Inc at Wells Fargo Healthcare Conference TranscriptSep 07, 2023
- Kezar Life Sciences Inc at Jefferies Healthcare Conference TranscriptJun 08, 2023
- Kezar Life Sciences Inc R&D Day TranscriptMar 15, 2023
- Alpine Immune Sciences Inc and Kezar Life Sciences Inc at Cowen Health Care Conference- Panel TranscriptMar 07, 2023
- Kezar Life Sciences Inc at JPMorgan Healthcare Conference TranscriptJan 11, 2023
- Kezar Life Sciences Inc at Evercore ISI HealthCONx Conference (Virtual) TranscriptNov 30, 2022
- Kezar Life Sciences Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 14, 2022
- Kezar Life Sciences Inc Topline Results from the MISSION Phase 2 Clinical Trial Evaluating Zetomipzomib - Corporate Call TranscriptJun 27, 2022
- Kezar Life Sciences Inc Annual Shareholders Meeting TranscriptJun 25, 2021
- Kezar Life Sciences Inc At TMA's International Annual Patient Conference TranscriptSep 22, 2020
- Q2 2020 Kezar Life Sciences Inc Earnings Call TranscriptAug 05, 2020$4.72 (+1.83%)Earnings
- Kezar Life Sciences Inc At MSU: Rare Disease Day Presentation TranscriptApr 15, 2020
- Kezar Life Sciences Inc At PRESIDIO Clinical Trial of KZR-616 TranscriptMar 05, 2020
Alpine Immune Sciences Inc and Kezar Life Sciences Inc at Cowen Health Care Conference- Panel Transcript
Thanks, everybody, for joining the Autoimmune/Complement/Inflammation panel. With us today, we have three companies: we have Alpine Immune Sciences, we have Mitch Gold or the CEO of Alpine; we have Noreen Henig from Kezar Life Sciences; and we have Jonathan Zalevsky from Nektar Therapeutics. Thanks for our panelists for joining.
Questions & Answers
We're going to start our discussion with some thematic questions, and then we're going to dive into a company-specific question. So in thematic questions, according to our consultants and experts in the field, some drug failures, certainly in autoimmune conditions may not be primarily due to efficacy, but also due to complex scoring system and complex endpoints being used. What steps have you taken to get past some of these challenges? And how do you think the FDA is going to respond to some of these potential changes in endpoints?
I guess, why don't we just start out with Mitch, and we're going to go progressively disorder.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)